Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $39.7 million.

  • Relay Therapeutics' Cash from Investing Activities rose 13148.73% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.3 million, marking a year-over-year increase of 189115.64%. This contributed to the annual value of -$41.1 million for FY2024, which is 11594.63% down from last year.
  • As of Q3 2025, Relay Therapeutics' Cash from Investing Activities stood at $39.7 million, which was up 13148.73% from $75.1 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Cash from Investing Activities ranged from a high of $75.3 million in Q1 2023 and a low of -$292.7 million during Q4 2021
  • Moreover, its 5-year median value for Cash from Investing Activities was $29.0 million (2024), whereas its average is -$15.5 million.
  • In the last 5 years, Relay Therapeutics' Cash from Investing Activities plummeted by 56380.06% in 2021 and then skyrocketed by 30323.81% in 2025.
  • Relay Therapeutics' Cash from Investing Activities (Quarter) stood at -$292.7 million in 2021, then skyrocketed by 49.81% to -$146.9 million in 2022, then skyrocketed by 140.61% to $59.7 million in 2023, then tumbled by 51.41% to $29.0 million in 2024, then surged by 36.99% to $39.7 million in 2025.
  • Its Cash from Investing Activities was $39.7 million in Q3 2025, compared to $75.1 million in Q2 2025 and $42.5 million in Q1 2025.